Forward Pharma to Participate in the Fall Investor Summit in New York
September 05 2019 - 8:30AM
Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today
announced that Chief Executive Officer, Dr. Claus Bo Svendsen,
will participate in the Fall Investor Summit investor
conference (https://www.microcapconf.com) in New York,
NY. Dr. Svendsen will present a corporate update on Tuesday,
September 17, 2019 at 8:00 AM ET and will be available for
one-on-one meetings.
About Forward Pharma:
Forward Pharma A/S is a Danish biopharmaceutical company that
commenced development in 2005 of a proprietary formulation of DMF
for the treatment of inflammatory and neurological indications. The
Company granted to Biogen an irrevocable license to all of its IP
through the Settlement and License Agreement and received from
Biogen a non-refundable cash fee of $1.25 billion in February 2017,
with the return of EUR 917.7 million to shareholders through a
capital reduction in September 2017. The Company has the
opportunity to receive royalties from Biogen on sales of Tecfidera®
or other DMF products for MS outside the U.S., dependent on, among
other things, a favorable outcome in Europe with respect to the
EP2801355 Opposition Proceeding, including any appeal thereto.
The principal executive offices are located at Østergade 24A,
1st Floor, 1100 Copenhagen K, Denmark and our American Depositary
Shares are publicly traded on the Nasdaq Stock Market (FWP). For
more information about the Company, please visit our website at
http://www.forward-pharma.com.
Forward Pharma A/S Investor Relations
Contact:
Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive
Officer Investor Relations investors@forward-pharma.com
Solebury Trout John Graziano jgraziano@troutgroup.com +1 (646) 378
2942
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Jul 2023 to Jul 2024